



Scientific Symposium

What can NGS do for biosafety of ATMP's?

Dr. Arnoud Boot

Abstract

The recent release of the ICH Q5A (R2) guidelines endorses the use of Next Generation Sequencing (NGS) based approaches for testing adventitious viruses in biological products. This represents a promising opportunity to expedite and refine the manufacturing processes of Advanced Therapy Medicinal Products (ATMPs), while maintaining rigorous standards of product quality and safety.

During this talk, we will delve into the potential of NGS-based methods for the detection of adventitious viruses. By leveraging NGS technology, manufacturers have the potential to reduce lead times by several weeks without sacrificing sensitivity, and while increasing specificity



April 24th, 2024,
9:00 to 17:00



Solvias AG, Römerpark 2, 4303
Kaiseraugst, Switzerland



Free



For inquiries or assistance with registration, please contact us at marketing@solvias.com.